Efanesoctocog Alfa

4 trials 3 recruiting BHaematology Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

1 Sponsors

15 Countries

Phase III

Phase IV

Phase III: 2 Phase IV: 2

Sponsors using this IMP

Swedish Orphan Biovitrum AB (publ) 4

All trials

4 total

Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting

2023-506537-29-00 Phase III 10 countries Swedish Orphan Biovitrum AB (publ)
A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly… Recruiting

2022-500275-31-00 Phase III 14 countries Swedish Orphan Biovitrum AB (publ)
Long-term study evaluating joint health in people with haemophilia A receiving real-world prophylactic treatment with efanesoctocog alfa Recruiting

2024-517812-31-00 Phase IV 8 countries Swedish Orphan Biovitrum AB (publ)
A study to investigate the course of synovial hypertrophy in patients with haemophilia A on efanesoctocog alfa prophylaxis Ended

2024-512066-33-00 Phase IV 4 countries Swedish Orphan Biovitrum AB (publ)

Showing 1–4 of 4 trials

← All drugs A–Z